Replies to post #3052 on Galectin Therapeutics Inc. (GALT)

[jmh0602]

Absolutely except primarily targeting lung fibrosis with inhalers, and nothing to do with NASH. I get the value comparison with GALT and believe we should be valued much higher, but just have to wait until the day we get a partner or buyout. The p1 cohort 2 and fx fiascos certainly didn't help. Seems the momentum has finally shifted so hopefully soon.